Successful treatment of refractory prurigo nodularis with abrocitinib

被引：2

作者：

Sun, Fang ^{[1
]}

Wu, Zhenzhen ^{[1
]}

机构：

[1] Jiangsu Univ, Affiliated AoYang Hosp, Derpartment Dermatol, Zhangjiagang 279 Gangcheng Rd, Zhangjiagang, Jiangsu, Peoples R China

来源：

CLINICAL CASE REPORTS | 2024年 / 12卷 / 03期

关键词：

abrocitinib; itching; JAK inhibitor; prurigo nodularis;

D O I：

10.1002/ccr3.8606

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Prurigo nodularis is frequently difficult to manage with conventional therapy. Given the pathogenesis and refractory nature, we demonstrate a case in which inhibition of JAK-STAT signaling may significantly improve prurigo nodularis. Based on the results, we would like to draw a conclusion that abrocitinib as an inhibitor of Jak is a promising choice for the treatment of prurigo nodularis.

引用

页数：2

共 3 条

[1] Effectiveness of baricitinib in prurigo-type atopic dermatitis: A case report
He, Yihong
Ji, Suyun
Yu, Qinghong
[J]. DERMATOLOGIC THERAPY, 2021, 34 (02)
[2] Breaking the Itch-Scratch Cycle in Prurigo Nodularis
Kwatra, Shawn G.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (08) : 757 - 758
[3] Successful treatment of recalcitrant nodular prurigo with tofacitinib
Molloy, O. E.
Kearney, N.
Byrne, N.
Kirby, B.
[J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2020, 45 (07) : 918 - 920

← 1 →